David M. Loeb

https://assets.montefioreeinstein.org/profiles/images/Loeb_David_MD_2x.jpg

First Name

David

Last Name

Loeb

NPI

1841236676

Faculty ID

15556

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Loeb has an active translational research laboratory focused on understanding bone tumor metastasis.&nbsp; His laboratory developed a clinically relevant mouse model of sarcoma metastasis, and has used this model to perform preclinical testing of novel agents that can interfere with this process.&nbsp; More basic scientific studies in the lab involve exploring the role of the Wnt signaling pathway in Ewing sarcoma migration, invasion, and metastasis.&nbsp; Dr. Loeb is also studying the role of an enzyme called RNA helicase DDX3 in Ewing sarcoma biology, especially how this enzyme affects the repair of damaged DNA. More recently, the laboratory has developed an interest in targeting the metabolic reprogramming associated with metastasis as a way to prevent the outgrowth of distant metastases from disseminated tumor cells.</p>
<p>&nbsp;</p>
<p>Dr. Loeb is also actively involved in clinical research, including the development of radiopharmaceutical agents for the treatment of bone metastases and the development of a small molecule inhibitor of DDX3.&nbsp; He serves as the local PI for a clinical trial of reduced intensity haploidentical bone marrow transplantation for children with high risk solid tumors.&nbsp; Finally, as an offshoot of his laboratory work, Dr. Loeb is involved in the development of biomarkers of metastatic risk and of minimal residual disease in children, adolescents, and young adults with sarcomas.</p>

Research Areas

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Loeb is a leading pediatric oncologist and NIH-funded researcher. He has extensive expertise in sarcoma research and clinical care and is a bone marrow transplantation specialist. Dr. Loeb’s research spans the spectrum from basic and translational studies to clinical trials using novel therapies.</p>

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Elsevier Profile

Selected Publications

<p>Dr. Loeb's PubMed bibliography can be found here: &nbsp;</p>
<p><a href="https://www.ncbi.nlm.nih.gov/sites/myncbi/1fiIspwqfwUE46/bibliography/5…;

EMR ID

6405

Biography

<p>David Loeb, MD, PhD, is Chief, Pediatric Hematology, Oncology and Cellular Therapy at Children&rsquo;s Hospital at Montefiore and Professor, Pediatrics and Professor, Developmental and Molecular Biology at Montefiore Einstein. His clinical work focuses on tumors of connective tissue, such as bone and muscle. He also has expertise in the care of children with other solid tumors. As a member of the bone marrow transplantation team, Dr. Loeb also cares for patients with acute leukemias and has expertise in the application of immunotherapy to childhood cancer.</p><p>Dr. Loeb earned his Bachelor of Arts in biology in 1987 at Johns Hopkins University. In 1993, he received his Doctor of Philosophy in Pathology and, in 1994, his Doctor of Medicine at Columbia University. In 1994, he also began an internship in Pediatrics at the Johns Hopkins University School of Medicine, followed by a residency in 1995 and a fellowship in Pediatric Hematology Oncology at the same institution.</p><p>Dr. Loeb has an active translational research laboratory focused on understanding bone tumor metastasis. His laboratory developed a clinically relevant mouse model of sarcoma metastasis and has used this model to perform preclinical testing of novel agents that can interfere with this process. One area of focus is the metabolic differences between cancer cells and normal cells, and between metastases and the primary tumor, with the intention of targeting these differences therapeutically. More basic scientific studies in the lab involve exploring the role of the Wnt signaling pathway in Ewing sarcoma and osteosarcoma migration, invasion and metastasis. Dr. Loeb also studies the role of an enzyme called RNA helicase DDX3 in Ewing sarcoma biology, especially how this enzyme affects the repair of damaged DNA.</p><p>Dr. Loeb is also actively involved in clinical research, including the development of radiopharmaceutical agents for the treatment of bone metastases and the development of a small molecule inhibitor of DDX3. He has also directed a clinical trial of reduced intensity haploidentical bone marrow transplantation for children with high risk solid tumors. Stemming from his laboratory work, Dr. Loeb is involved in the development of biomarkers of metastatic risk and of minimal residual disease in children, adolescents and young adults with sarcomas. Dr. Loeb&rsquo;s original research, based on his clinical and laboratory studies, has been published in multiple journals and books.</p><p>Dr. Loeb has been a recipient of many awards, including the Director&rsquo;s Teaching Award in Clinical Science from Sidney Kimmel Comprehensive Cancer Center in 2006, 2010 and 2015, and The Justin Straus Chordoma Research Award in 2009.</p>

Is Open Scheduling

Off

Anna Y. Zolotnitskaya

https://assets.montefioreeinstein.org/profiles/images/Zolotnitskaya_Anna_MD_2x_0.jpg

First Name

Anna

Last Name

Zolotnitskaya

NPI

1316949100

Faculty ID

1899

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Elsevier Profile

EMR ID

31006

Biography

<p>Anna Zolotnitskaya, MD, is Medical Director, Pediatric Dialysis at the Children&rsquo;s Hospital at Montefiore Einstein and Assistant Professor, Pediatrics at our Albert Einstein College of Medicine. Dr. Zolotnitskaya&rsquo;s clinical focus is on pediatric dialysis and pediatric renal transplantation. She leads a multidisciplinary dialysis team that provides patient-centered, evidence-based care for children and young adults with end-stage kidney disease. </p><p>After obtaining her Doctor of Medicine at St. Petersburg Pediatric Academy in St. Petersburg, Russia, in 1983, Dr. Zolotnitskaya completed her pediatrics internship at the same institution in 1984. She remained there to complete her pediatrics residency in 1989, before completing an additional pediatrics residency at Soroka Medical Center in Beer-Sheva, Israel, in 1994. Following this, Dr. Zolotnitskaya completed a pediatric nephrology fellowship at Montefiore Einstein in 1998, followed by an additional pediatrics residency at Columbia University College of Physicians and Surgeons, St. Luke&rsquo;s-Roosevelt Hospital in 2001. </p><p>Dr. Zolotnitskaya has been principal investigator and co-investigator in clinical trials that investigate medications employed for the care of children with advanced chronic kidney disease. Her work has been published in numerous peer-reviewed journals and abstracts, and she has given several invited presentations. She is also a reviewer for the <em>Journal of Pediatrics: Clinical Practice</em>. </p><p>Dr. Zolotnitskaya is board certified by the American Board of Pediatric Nephrology, the American Board of Pediatrics and the Israeli Board of Pediatrics. She is a member of the American Academy of Pediatrics, the American Society of Nephrology and the American Society of Pediatric Nephrology.

</p>

Is Open Scheduling

Off

Lili Zhang

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/acc2b8e0-d37c-11eb-9aaf-2d15ec0e1e68.jpg

First Name

Lili

Last Name

Zhang

NPI

1992066948

Faculty ID

16495

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Non-invasive cardiology, echocardiography, cardio-oncology, multimodality cardiovascular imaging

Research Focus

Cardiotoxicity of cancer therapy, immune checkpoint inhibitor myocarditis, and the application of multimodality imaging and machine-learning techniques in cardiovascular disease.

Elsevier Profile

EMR ID

56187

Biography

<p>Lili Zhang, MD, is Director, Cardio-Oncology Program and Assistant Professor, Cardiology at Montefiore Einstein. A non-invasive cardiologist and a cardiac imaging specialist, Dr. Zhang&rsquo;s clinical focus is in Cardio-Oncology, cardiomyopathy, general cardiology, echocardiography and multimodality cardiac imaging.</p><p>In 2007, Dr. Zhang earned her Doctor of Medicine degree at Peking University, Beijing, China. Further education and postdoctoral training brought her to the U.S., completing her Master of Science in Epidemiology at Johns Hopkins Bloomberg School of Public Health in 2011. She then came to Einstein, completing her residency in internal medicine in 2015 and her fellowship in cardiology in 2018. In 2019, Dr. Zhang completed her fellowship in Cardio-Oncology and cardiac imaging at Massachusetts General Hospital.</p><p>Dr. Zhang&rsquo;s research focuses on cardiotoxicity of cancer therapy, immune checkpoint inhibitor myocarditis, cardiovascular care and the application of multimodality imaging and machine-learning techniques in cardiovascular disease. Her research experience includes retrospective studies, prospective cohorts (ARIC and CHS), large multi-cohort consortiums (CHARGE and PAGE consortiums), randomized clinical trials (PROMISE trial), and international collaborative registries (international immune checkpoint inhibitor myocarditis registry and Global Cardio Oncology Registry). She has shared her work through more than 60 manuscripts in peer-reviewed journals and abstract publications.</p><p>Dr. Zhang is board certified in Internal Medicine and Cardiovascular Disease. She is a Fellow of the American College of Cardiology, and is a member of the American Heart Association and the international Cardio-Oncology Society. In 2021, she was awarded the Glorney-Raisbeck Junior Faculty Research Award in Cardiovascular Disease by New York Academy of Medicine.</p>

Is Open Scheduling

Off

Samson Wiseman

https://assets.montefioreeinstein.org/profiles/images/physphoto/Wiseman_Samson_MD_420x504.jpg

First Name

Samson

Last Name

Wiseman

NPI

1588761316

Faculty ID

10181

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

4748

Is Open Scheduling

Off

Daniel A. Weiser

https://assets.montefioreeinstein.org/profiles/images/Weiser_Daniel_MD_2x.jpg

First Name

Daniel

Last Name

Weiser

NPI

1225239700

Faculty ID

13846

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><span style="text-decoration: underline;"><strong>Childhood cancer research laboratory</strong></span></p>
<p>Our laboratory is focused on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. In such patients with typically incurable cancer, we are striving to identify new approaches to and types of treatment. We have multiple ongoing projects:</p>
<p><strong>+ Identification of biologic drivers of ultra-high-risk neuroblastoma</strong>. Neuroblastoma is one of the most common and deadly childhood cancers. Despite intensive research, there are limited therapeutic strategies for patients with <em>de novo </em>chemotherapy resistance that leads to particularly poor outcomes. We have been studying neuroblastoma since 2009 and are identifying additional biologic drivers of highly lethal tumors.</p>
<p>We compare tumor features from patients with early death from tumor progression compared to those with a maintained complete response. We assess unique histo-morphologic and proteomic features and computationally integrate these data with genomic and transcriptomic datasets to develop a combined predictor of primary refractory disease. Patients with this entity require non-standard and/or intensified treatment. Oncogenic drivers are being characterized in the lab which will facilitate strategies for novel pharmacologic intervention.</p>
<p><strong>+ Characterization of neuroblastoma development from neural crest cells</strong>.&nbsp; We are studying pathways and interactions that results in uncontrolled cell proliferation early in neuroblastoma development with an ultimate goal of identifying new targets and approaches for pharmacologic intervention.</p>
<p><strong>+ Evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma</strong>.&nbsp; With expected outcomes lagging behind those of more common childhood cancers, children with neuroblastoma require new approaches to treatment. Our lab works with multiple international clinical and research consortium groups to perform preclinical studies that substantiate human clinical trials.&nbsp;</p>
<p><strong>+ Detection of circulating tumor DNA in osteosarcoma</strong>. With no reliable non-invasive approach for disease monitoring during and after treatment, we are applying cutting edge next-generation sequencing approaches to identify solid tumors with a blood-based &ldquo;liquid&rdquo; biopsies. This will allow clinicians to assess tumor responsiveness to chemotherapy and predict likelihood of recurrence.</p>
<p><strong>+ Assessment of accelerated aging using miRNA-seq in survivors of childhood cancer</strong>. Chemotherapy has many untoward effects on healthy cells and leads to many signs of accelerated aging in children treated for cancer. Using a known microRNA &ldquo;aging&rdquo; signature discovered at Albert Einstein College of Medicine, we are studying what causes this phenotype in childhood cancer, with a goal of offering improved intervention to minimize long-term toxicity of treatment.</p>
<p><strong><span style="text-decoration: underline;">Physician Summary</span></strong></p>
<p>Daniel A. Weiser, MD, is board-certified in pediatric hematology/oncology with clinical expertise in neuroblastoma and other tumors of the adrenal glands, kidneys, liver, and gonads. He is the medical director of the intra-abdominal solid tumor program at the Children&rsquo;s Hospital at Montefiore and brings together a highly specialized multi-disciplinary care team to provide comprehensive treatment for diverse pediatric malignancies. In addition, Dr. Weiser directs a childhood cancer research laboratory that focuses on the identification of new targeted agents for cancer therapy, especially in the treatment of rare and aggressive malignancies such as neuroblastoma. His research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise for improving management of all patients with solid tumors.</p>
<p>Dr. Weiser participates in the efforts of a number of professional organizations including the Children&rsquo;s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), Advances in Neuroblastoma Research Association (ANRA), National Pediatric Cancer Foundation (NPCF), and the American Academy of Pediatrics (AAP). He has received numerous awards including the Brigid Leventhal Special Merit Award from ASCO and the Conquer Cancer Foundation, and a prestigious K12 from the National Cancer Institute for the training of the next generation of physician-scientists in pediatric cancer. Dr. Weiser is actively involved in teaching and mentorship of trainees, and takes great pride in providing advanced and compassionate care to his patients and their families.</p>
<p><strong>Clinical Expertise</strong></p>
<ul>
<li>Neuroblastoma (adrenal tumors)</li>
<li>Wilms tumor (renal tumors)</li>
<li>Hepatoblastoma (liver tumors)</li>
<li>Germ cell tumors (including testicular and ovarian tumors)</li>
<li>Thyroid and other rare tumors</li>
<li>Experimental therapeutics</li>
<li>Cancer genetics and biomarkers</li>
</ul>
<p><strong>Board Certifications</strong></p>
<ul>
<li>Pediatrics</li>
<li>Pediatric Hematology/Oncology</li>
</ul>
<p><strong>Professional Education</strong></p>
<ul>
<li>M.D. &ndash; Stony Brook University, NY</li>
<li>Residency &ndash; Children&rsquo;s Hospital of NY-Presbyterian, Columbia University, NY</li>
<li>Chief Residency &ndash; Children&rsquo;s Hospital of NY-Presbyterian, Columbia University, NY</li>
<li>Fellowship &ndash; The Children&rsquo;s Hospital of Philadelphia, PA</li>
</ul>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Clinical Focus

DR. Weiser's clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma, and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers.&nbsp;

Research Focus

Dr. Weiser&rsquo;s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser&rsquo;s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others.

Elsevier Profile

EMR ID

5755

Biography

<p>Daniel A. Weiser, MD, is a Medical Director of the Intra-abdominal Solid Tumor Program in the Pediatrics Hematology/Oncology department at Children&rsquo;s Hospital at Montefiore. He is also Associate Professor in the Pediatrics and Genetics departments at the Albert Einstein College of Medicine. His clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers. Dr. Weiser is actively involved in teaching and mentorship of trainees and takes great pride in his active participation in patient care.</p><p>Dr. Weiser received his Bachelor of Science in Neurobiology in 1995 at Haverford College, PA. In 2004, he received his Doctor of Medicine at Stony Brook University School of Medicine, NY. He is currently earning his Master of Science in Translational Research at the University of Pennsylvania. He began a residency in Pediatrics at the New York-Presbyterian, Columbia University in 2007. Dr. Weiser then completed a three-year fellowship in Pediatric Hematology/Oncology at The Children&rsquo;s Hospital of Philadelphia. </p><p>Dr. Weiser&rsquo;s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser&rsquo;s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others. His research has been published in many reviewed journals. </p><p>Dr. Weiser participates in the efforts of a number of professional organizations including the Children&rsquo;s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), and the American Academy of Pediatrics (AAP). He has received many awards including the Brigid Leventhal Special Merit Award through ASCO, and he has been awarded a prestigious K12 from the NCI for the training of the next generation of physician-scientists in pediatric cancer.</p><p>He is board certified in Pediatric Hematology/Oncology and General Pediatrics.</p>

Is Open Scheduling

Off

Jacqueline Weingarten-Arams

https://assets.montefioreeinstein.org/profiles/images/physphoto/Weingarten_Jacqueline_MD_420x504.jpg

First Name

Jacqueline

Last Name

Weingarten-Arams

NPI

1558447409

Faculty ID

4831

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Areas

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Elsevier Profile

Lab Website Link

EMR ID

3961

Biography

<p>Jacqueline Weingarten-Arams, MD, is an attending physician and Professor, Pediatrics at Montefiore Einstein. Dr. Weingarten-Arams&rsquo; pediatric critical care expertise focuses on cardiac critical care, acute hypoxemic respiratory failure, nutrition in critical illness and energy expenditure, cardiopulmonary resuscitation (quality CPR) and extracorporeal life support (ECMO).</p><p>After obtaining her Bachelor of Science in nutritional biochemistry at Cornell University in 1982, Dr. Weingarten-Arams earned her Doctor of Medicine at the same institution in 1986. She then completed her pediatric residency at Columbia University in 1990, where she was Chief Resident in her final year. Following this, Dr. Weingarten-Arams completed a fellowship in pediatric critical care medicine at New York Hospital Cornell University Medical College in 1996.</p><p>Dr. Weingarten-Arams research focus includes the use of deliberate simulated practice in improving outcomes in pediatric critical illness, pediatric resuscitation and pediatric airway management. Her other projects involve chronic critical illness, bioethics in pediatric critical care and oxidative injury in respiratory failure. She has been principal investigator and co-investigator on several research projects, and her work has been shared through numerous peer-reviewed publications and invited presentations.</p><p>Dr. Weingarten-Arams is a Diplomate of the National Board of Medical Examiners and the American Board of Pediatrics. She is a Fellow of the American Academy of Pediatrics and the American College of Chest Physicians. She is also a member of several professional organizations, including the American Medical Association, the Pediatric Cardiac Intensive Care Society and the Society of Critical Care Medicine. Dr. Weingarten-Arams has been named in Castle Connolly&rsquo;s &ldquo;Top Doctors: New York Metro Area&rdquo; for multiple years. In 2006, she was inducted into the Leo M. Davidoff Society and in 2019, Dr. Weingarten-Arams won the William Obrinsky Award for Excellence in Medical Student Education.</p>

Is Open Scheduling

Off

Dawn M. Wahezi

https://assets.montefioreeinstein.org/profiles/images/Wahezi_Dawn_MD_MS_2x.jpg

First Name

Dawn

Last Name

Wahezi

NPI

1518290725

Faculty ID

11304

CMO Specialties

Clinical Terms

Employment Status

part-time

Patient Type

Pediatric

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Wahezi attended medical school at the University of Buffalo, School of Medicine and Biomedical Sciences. She completed her residency training in Pediatrics at The Children&rsquo;s Hospital at Montefiore, where she stayed on as the inaugural fellow in Pediatric Rheumatology. She subsequently joined the faculty in the Department of Pediatrics at Montefiore and completed a Master&rsquo;s Degree in clinical research through the Einstein-Montefiore Institute for Clinical and Translational Research Program. Dr. Wahezi is currently an Assistant Professor of Pediatrics at the Albert Einstein College of Medicine and serves as the Program Director of the Pediatric Rheumatology Fellowship Program.&nbsp;</p>
<p>Dr. Wahezi has a special interest in juvenile dermatomyositis (JDM) and was awarded the Cure JM Foundation Early Investigator Award for her research in premature atherosclerosis. She has additionally established a pediatric Systemic Lupus Erythematosus (SLE) Cohort and participates in a dedicated, multi-disciplinary pediatric Lupus Nephritis Clinic. Dr. Wahezi is currently engaged in several research projects within the domains of JDM and SLE, contributing to over 40 peer reviewed manuscripts, reviews and scientific abstracts.</p>
<p>Dr. Wahezi is an active member of both the JDM subcommittee and SLE subcommittee within the Childhood Arthritis and Rheumatology Research Alliance (CARRA) and has participated in numerous observational and comparative&nbsp;effectiveness research protocols through this research consortium. &nbsp;</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

<span style="color:#4d4d4d;font-family:Arial, Helvetica, source-code-pro, Menlo, Monaco, Consolas, 'Courier New', monospace;font-size:16px;background-color:#ffffff;">Pediatric Rheumatology</span>

Research Focus

Dr. Wahezi has a particular research interest in juvenile dermatomyositis (JDM) and was awarded the Cure JM Foundation Early Investigator Award for her research in premature atherosclerosis.

Elsevier Profile

EMR ID

4724

Biography

<p></p>Dawn Wahezi, MD, MS, is Chief of the Division of Pediatric Rheumatology and Director of the Pediatric Rheumatology Fellowship Program at the Children&rsquo;s Hospital at Montefiore. She is also Associate Professor of Pediatrics at our Albert Einstein College of Medicine.<br /><br />Dr. Wahezi received her Bachelor of Science from Loyola College and earned her Doctor of Medicine at the State University of New York at Buffalo, Jacobs School of Medicine and Biomedical Sciences. She obtained a Master of Science in Clinical Research at Albert Einstein College of Medicine, and did her residency and fellowship training at CHAM.<br /><br />Dr. Wahezi&rsquo;s clinical and research interests include juvenile dermatomyositis (JDM) and juvenile systemic lupus erythematosus (SLE). At CHAM, she established an interdisciplinary clinic and comprehensive patient registry for children with JDM and SLE.. Dr. Wahezi is an active member of the American Academy of Pediatrics Rheumatology Advisory Board and the Childhood Arthritis and Rheumatology Research Alliance (CARRA).<p></p>

Is Open Scheduling

On

Zocdoc Link

Henry Michael Ushay

https://assets.montefioreeinstein.org/profiles/images/physphoto/Ushay_Michael_MD_420x504.jpg

First Name

Henry

Last Name

Ushay

NPI

1558332007

Faculty ID

10275

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Clinical Focus

Pediatric critical care medicine with a special emphasis on respiratory failure; shock resuscitation; cardiac intensive care; intensive care of pediatric oncology patients; extracorporeal support for children with respiratory and cardiovascular failure

Research Focus

Leadership and direction of the 16-bed Pediatric Critical Care Unit of The Children&rsquo;s Hospital at Montefiore; improving medication safety; respiratory physiology; advances in the management of respiratory failure in children; shock; medical ethics

Elsevier Profile

EMR ID

4763

Biography

<p>Dr. Ushay is Professor of Clinical Pediatrics in the Albert Einstein College of Medicine. He is a Fellow of the American Academy of Pediatrics as well as a Fellow of the American College of Critical Care Medicine. </p><p>After obtaining a PhD in Chemistry from Columbia University, Dr. Ushay received his MD from UMDNJ-New Jersey Medical School and completed a Pediatrics residency in the Montefiore-Jacobi-Einstein program. After serving as Chief Resident and a Fellow in Pediatric Pulmonology at Montefiore, he completed a Pediatric Critical Care Fellowship at New York Hospital/Cornell Medical Center in 1993. He was a faculty member at NewYork-Presbyterian and Memorial Sloan-Kettering Hospitals from 1993 to 2005, and he served as Pediatric Critical Care Medicine Fellowship Program Director and Medical Director of the Pediatric Observation Unit at Memorial Sloan-Kettering Cancer Center. </p><p>In 2005 Dr. Ushay became Director of the Pediatric Critical Care Unit in The Children&rsquo;s Hospital at Montefiore. Dr. Ushay is involved in increasing pediatric ICU surge capacity through the New York City Pediatric Disaster Coalition, serving on its Central Leadership Council and teaching the Pediatric Fundamental Critical Care Support Course. Through the National Institute of Child Health and Human Development, Dr. Ushay works on employing medical countermeasures safely for children in the event of chemical, biological or radiological disaster. Sponsored by Surgeons of Hope and Children&rsquo;s HeartLink, Dr. Ushay has worked as a cardiac intensivist in Cambodia, Africa, China and Nicaragua. </p>

Is Open Scheduling

Off

Alecia M. Thompson

https://assets.montefioreeinstein.org/profiles/images/Thompson_Alecia_MD_420x540.jpg

First Name

Alecia

Last Name

Thompson

NPI

1992930796

Faculty ID

12295

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

CHAM Provider

On

Professional Title

Research Focus

Dr. Thompson-Branch's research has focused on the role of cytokines in bronchopulmonary dysplasia and use of ultrasound to diagnose necrotizing enterocolitis.

Elsevier Profile

EMR ID

5397

Biography

<p>With an emphasis on general pediatrics and neonatology, Dr. Thompson completed her residency at NYU Medical Center in 2007 and fellowship at Yale-New Haven Hospital in 2010. During her fellowship, Dr. Thompson also audited the Robert Wood Johnson Clinical Scholars Program, with an interest in performing clinical research. Her research has focused on the role of cytokines in bronchopulmonary dysplasia and use of ultrasound to diagnose necrotizing enterocolitis. She plans to conduct research on the use of near-infrared spectroscopy to delineate central nervous system pathology in preterm infants and predict short-term neurologic outcomes.</p>

Is Open Scheduling

Off

Ivy Tam

https://assets.montefioreeinstein.org/profiles/images/physphoto/Tam_Ivy_MD_420x504.jpg

First Name

Ivy

Last Name

Tam

NPI

1427494269

Faculty ID

15947

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Clinical Focus

Pediatric Medicine

Research Focus

Dr. Tam&rsquo;s research aims to improve care and communication for patients with limited English proficiency, as well as standardizing pain practices for children.&nbsp;

Elsevier Profile

EMR ID

14829

Biography

<p>Ivy Tam, MD, FAAP, is an Attending Physician and a Non-neonatal Emergency Transport Coordinator at Children&rsquo;s Hospital at Montefiore. She is also an Assistant Professor of Pediatrics at our Albert Einstein College of Medicine. </p><p>In 2009, Dr. Tam received her Bachelor of Arts in Biological Sciences at Cornell University. She then attended SUNY Upstate Medical University, where she received her Doctor of Medicine in 2013. Dr. Tam began her postgraduate training with a residency in pediatrics at New York University School of Medicine, followed by a fellowship in pediatric hospital medicine in 2018 at the University of California San Diego. </p><p>Dr. Tam&rsquo;s research aims to improve care and communication for patients with limited English proficiency, as well as standardizing pain practices for children. She has shared her work through presentations in academic forums and scientific meetings, and is currently in the process of being submitted for publication. </p><p>2017, Dr. Tam received the CARES Award from hospital staff at Rady Children&rsquo;s Hospital for her support during the medical director&rsquo;s absence. Dr. Tam is board certified by the American Board of Pediatrics and is a member of the American Academy of Pediatrics. </p>

Is Open Scheduling

Off